Development and analytical evaluation of a microneutralization cytopathic effect assay for human adenovirus type 55-specific neutralizing antibodies
Journal of Microbiology · 31.07.2026 · 64 (7) · e2604007
DOI: 10.71150/jm.2604007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Microbiology, erschienen am 31.07.2026. Verfasst von Dae-Im Jung und 6 weiteren Autor:innen. Beteiligte Einrichtung: Science Unit, International Vaccine Institute, Seoul 08826, Republic of Korea. Hauptthemen laut MEDLINE: Adenoviruses, Human, Antibodies, Neutralizing, Neutralization Tests, Antibodies, Viral. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea Health Industry Development Institute, Ministry of Health and Welfare.
Abstract (Originalsprache)
Reliable quantification of neutralizing antibodies (nAb) against human adenovirus type 55 (HAdV-55) is critical for the evaluation of emerging vaccine candidates. While the plaque reduction neutralization test (PRNT) is currently the reference standard, its utility for large-scale studies is limited by low throughput, labor-intensive plaque counting, and prolonged assay times. In this study, we established and analytically validated a microneutralization assay based on cytopathic effect (MN-CPE) as a scalable alternative for HAdV-55-specific nAb quantification. Comparative performance analysis revealed that both assays maintain high dilution linearity, with coefficients of determination (R2) of 0.988 for MN-CPE and 0.9926 for PRNT. Relative accuracy assessments using high-, middle-, and low-titer reference sera demonstrated acceptable responses across the dynamic range. Notably, the MN-CPE assay allowed for the definition of a negative-control acceptance range, providing a distinct statistical advantage over PRNT, where negative-control values were consistently zero. Furthermore, both assays successfully detected HAdV-55-specific nAbs in immunized cynomolgus macaques, with no cross-reactivity observed against other HAdV types such as HAdV-4. These findings indicate that the MN-CPE assay is analytically comparable to PRNT and serves as a practical, relatively high-capacity alternative for HAdV-55 neutralization testing in clinical and preclinical vaccine research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Science Unit, International Vaccine Institute, Seoul 08826, Republic of Korea.
- Department of Infectious Diseases, Armed Forces Medical Research Institute, Daejeon 34059, Republic of Korea.
- KeyPrime Research, Cheongju 28161, Republic of Korea.
Förderung
- Korea Health Industry Development Institute
- Ministry of Health and Welfare
Zitieren
APA
Jung, D. I., Park, Y., Choi, J. A., Kwon, S. H., Lee, J. Y., Song, M., & Seo, S. H. (2026). Development and analytical evaluation of a microneutralization cytopathic effect assay for human adenovirus type 55-specific neutralizing antibodies. Journal of Microbiology, 64(7), e2604007. https://doi.org/10.71150/jm.2604007
Vancouver
Jung DI, Park Y, Choi JA, Kwon SH, Lee JY, Song M, et al. Development and analytical evaluation of a microneutralization cytopathic effect assay for human adenovirus type 55-specific neutralizing antibodies. Journal of Microbiology. 2026;64(7):e2604007. doi:10.71150/jm.2604007
BibTeX
@article{Jung2026,
author = {Jung, Dae-Im and Park, Yunjeong and Choi, Jung-Ah and Kwon, Soon-Hwan and Lee, Jun Young and Song, Manki and Seo, Sang Hwan},
title = {Development and analytical evaluation of a microneutralization cytopathic effect assay for human adenovirus type 55-specific neutralizing antibodies},
journal = {Journal of Microbiology},
year = {2026},
volume = {64},
number = {7},
pages = {e2604007},
doi = {10.71150/jm.2604007}
}
EUVIMED